Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 4
Submit an article Journal homepage
286
Views
8
CrossRef citations to date
0
Altmetric
Theme: Gastrointestinal & Hepatopancreatobiliary Cancer - Review

The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer

Marwan Fakih Medical Oncology, City of Hope, 1500 Duarte Rd, Duarte, CA 91010, USA. [email protected]
Pages 427-438 | Published online: 10 Jan 2014

References

  • Adam R, Haller DG, Poston G et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer – an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann. Oncol. 21(8), 1579–1584 (2010).
  • Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J. Oncol. doi:10.1155/2010/652320 (2010) (Epub ahead of print).
  • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27–31 (1995).
  • Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671–680 (2005).
  • Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333(2), 328–335 (2005).
  • Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
  • Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert. Opin. Biol. Ther. 9(2), 263–271 (2009).
  • Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2(59), re1 (2009).
  • Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J. Chin. Med. Assoc. 73(9), 449–456 (2010).
  • Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012).
  • Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592–603 (2008).
  • Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6(6), 327–338 (2009).
  • Arnold D, Andre T, Bennouna J et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized Phase III intergroup study (TML study). Presented at: 2012 Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2012 (Abstract CRA3503).
  • Allegra CJ, Lakomy R, Tabernero J et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: a Phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. J. Clin. Oncol. 30(4 Suppl.), Abstract 3505 (2012).
  • Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298–307 (2011).
  • Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 1(7), 515–529 (2010).
  • Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25(4), 581–611 (2004).
  • Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(6), 735–745 (1998).
  • Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935), 1306–1309 (1989).
  • Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246(4935), 1309–1312 (1989).
  • Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380(6573), 439–442 (1996).
  • Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573), 435–439 (1996).
  • Hilmi C, Guyot M, Pagès G. VEGF spliced variants: possible role of anti-angiogenesis therapy. J. Nucleic Acids doi:10.1155/2012/162692 (2012) (Epub ahead of print).
  • Olofsson B, Korpelainen E, Pepper MS et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl Acad. Sci. USA 95(20), 11709–11714 (1998).
  • Aase K, von Euler G, Li X et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104(3), 358–364 (2001).
  • Li X, Lee C, Tang Z et al. VEGF-B: a survival, or an angiogenic factor? Cell. Adh. Migr. 3(4), 322–327 (2009).
  • Carmeliet P, Moons L, Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7(5), 575–583 (2001).
  • Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269(41), 25646–25654 (1994).
  • Wei SC, Tsao PN, Yu SC et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54(5), 666–672 (2005).
  • Fischer C, Jonckx B, Mazzone M et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3), 463–475 (2007).
  • Taylor AP, Osorio L, Craig R et al. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin. Cancer Res. 8(4), 1213–1222 (2002).
  • Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743–3748 (2008).
  • Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 134(5), 1296–1310 (2008).
  • Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182–1186 (1971).
  • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58–62 (2005).
  • Park JW, Kerbel RS, Kelloff GJ et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res. 10(11), 3885–3896 (2004).
  • Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28(22), 3617–3622 (2010).
  • Papadopoulos N, Martin J, Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2), 171–185 (2012).
  • Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99(17), 11393–11398 (2002).
  • Kopetz S, Hoff PM, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28(3), 453–459 (2010).
  • Rudge JS, Holash J, Hylton D et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl Acad. Sci. USA 104(47), 18363–18370 (2007).
  • Tew WP, Gordon M, Murren J et al. Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin. Cancer Res. 16(1), 358–366 (2010).
  • Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013–2019 (2008).
  • Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563–572 (2009). Erratum in: N. Engl. J. Med. 363(26), 2573 (2010).
  • Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672–680 (2009).
  • Stathopoulos GP, Batziou C, Trafalis D et al. Treatment of colorectal cancer with and without bevacizumab: a Phase III study. Oncology 78(5–6), 376–381 (2010).
  • Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol. 28(19), 3191–3198 (2010).
  • Fabbri F, Passardi A, Ravaioli A et al.; ITACa Study Group. Sequential treatment strategy for metastatic colorectal cancer: a Phase III study of chemotherapy (CT) with or without bevacizumab (Bev) as first-line therapy followed by two Phase III studies of CT alone or CT plus bev with or without cetuximab (Cetux) as second-line therapy (ITACa Study IRST 153 01). J. Clin. Oncol. 29(Suppl.), Abstract e14161 (2011).
  • Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539–1544 (2007).
  • Tabernero J, Van Cutsem E, Lakomy R et al. Results from VELOUR, a Phase III study of aflibercept (A) versus placebo (pbo) in combination with FOLFIRI for the treatment of patients (pt) with previously treated metastatic colorectal cancer (MCRC). Eur. J. Cancer 47(Suppl. 2), 5 Abstract 6LBA (2011).
  • Allegra CJ, Tabernero J, Rougier P et al. Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled Phase III trials with IV aflibercept (Afl). J. Clin. Oncol. 30(Suppl. 4), Abstract 561 (2012).
  • Kozloff M, Yood MU, Berlin J et al. Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14(9), 862–870 (2009).
  • Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26(33), 5326–5334 (2008).
  • Van Cutsem E, Rivera F, Berry S et al. First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20(11), 1842–1847 (2009).
  • Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomized Phase-III NO16966 trial. Br. J. Cancer 101(7), 1033–1038 (2009).
  • Cohn AL, Bekaii-Saab T, Bendell JC et al.; ARIES Study Investigators. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J. Clin. Oncol. 28(15 Suppl.), Abstract 3596 (2010).
  • Hurwitz H, Douglas P, Middleton J et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J. Clin. Oncol. 28(Suppl. 15), Abstract 3039 (2010).
  • Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary Phase II study. J. Clin. Oncol. 27(18), 3020–3026 (2009).
  • Pohl M, Werner N, Munding J et al. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z. Gastroenterol. 49(10), 1398–1406 (2011).
  • Jubb AM, Hurwitz HI, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24(2), 217–227 (2006).
  • Pectasides D, Papaxoinis G, Kalogeras K et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group Phase III trial with collateral biomarker analysis. BMC Cancer 12(1), 271 (2012).
  • Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20), 3239–3247 (2010).
  • Van Cutsem E, Jayson G, Dive C et al. ORAL analysis of blood plasma factors in the AVITA Phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC). Agr. Ecosyst. Environ. 47(Abstract 803), S95–S96 (2011).
  • Van Cutsem E, de Haas S, Kang YK et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized Phase III trial. J. Clin. Oncol. 30(17), 2119–2127 (2012).
  • Lieu CH, Tran HT, Jiang Z et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J. Clin. Oncol. 29(Suppl.), Abstract 3533 (2011).
  • Weickhardt AJ, Williams D, Lee C et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the Phase III MAX study. J. Clin. Oncol. 29(Suppl.), Abstract 3531 (2011).
  • Gerger A, El-Khoueiry A, Zhang W et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin. Cancer Res. 17(17), 5783–5792 (2011).
  • Koutras AK, Antonacopoulou AG, Eleftheraki AG et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics 16 12(6), 468–475 (2011).
  • Loupakis F, Ruzzo A, Salvatore L et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11, 247 (2011).
  • Lambrechts D, Claes B, Delmar P et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13(7), 724–733 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.